Emerging issues in stimulating apheresis platelet donors with platelet growth factors, the relative costs of apheresis and random donor platelet concentrates, optimal platelet transfusion dose, and leucoreduction of platelet products have caused renewed debate regarding apheresis products rs. random, pooled concentrates. The future role of apheresis products in platelet transfusion therapy will in large part be determined by costs, which are increasingly recognized to be influenced by donor platelet count, apheresis yield, and platelet transfusion dose.
|Original language||English (US)|
|Number of pages||6|
|Journal||Journal of clinical apheresis|
|State||Published - Nov 17 1998|
- Apheresis platelets
- Donor platelet count
- Platelet transfusion therapy